Telemonitoring of RAPID3 to deliver Treat-to-Target goal in RA
Research type
Research Study
Full title
Telemonitoring of RAPID3, a patient administered index to advise treat-to-target treatment in rheumatoid arthritis
IRAS ID
260522
Contact name
G A Mittal
Contact email
Sponsor organisation
Research and Innovation Centre
ISRCTN Number
ISRCTN16316564
Duration of Study in the UK
3 years, 0 months, 0 days
Research summary
Rheumatoid Arthritis (RA) causes multiple joints pain, swelling and stiffness but truly can affect the whole body. IT affects nearly half a million people in the UK and approximately 21,000 people in the country develop RA every year. With the dramatic advances in the drug treatment, most RA patients should be able to achieve remission. This unprecedented opportunity however is lost in at least 50% patients due to the nationwide shortfalls in implementing the NICE recommended treat-to-target management of RA. Poorly treated RA patients suffer joint damage, disability, shortened life span, are at high risk of losing employment and cost UK economy £2.4b annually. This situation can be prevented by advising treatment modification based on telemonitored RAPID3, a patient-administered measure of RA activity instead of the currently used DAS28, which is administered face-to-face by a clinician.
Our hypothesis is that telemonitored RAPID3 is equivalent to DAS28 in advising treatment modification towards achieving treat-to-target goal in RA. We plan to recruit newly diagnosed RA patients seen in the rheumatology clinics at the Royal National Orthopaedic Hospital. The patients will be randomised to telemonitored RAPID3 or clinic monitored DAS28 group. RA activity in both the groups will be measured every 4 weeks to advise treatment escalation until remission is achieved. The patients will be monitored every 4 weeks for the first 6 months and thereafter every 3 months for the next 6 months of the total 12 months of the study period.
Achieving treat-to-target strategy will allow reducing the adverse impact of RA on patients, wider society and economy.REC name
London - Westminster Research Ethics Committee
REC reference
19/LO/0673
Date of REC Opinion
24 Jul 2019
REC opinion
Further Information Favourable Opinion